3M Profit Outlook Light; Netflix Amends Warner Bros. Deal; GSK to Buy Rapt Therapeutics

On this episode of Stock Movers:
- 3M (MMM) shares fall after the industrial company gave an outlook for this year’s adjusted earnings per share with a midpoint below what analysts expected. JPMorgan says the company had a “mixed” end to 2025, with adjusted organic growth missing their estimate.
- Netflix (NFLX) reached an amended, all-cash agreement to buy Warner Bros. Discovery Inc.’s studio and streaming business as it battles Paramount Skydance Corp. to acquire one of Hollywood’s most iconic entertainment companies. Netflix, which previously agreed to pay $27.75 a share in cash and stock for the Warner assets, will pay the full amount in cash, according to a filing confirming an earlier Bloomberg News report on the revised terms. Warner Bros. plans to call a special meeting of shareholders to approve the deal. Netflix said stockholders should be able to vote on the transaction by April.
- GSK (GSK) agreed to buy Rapt Therapeutics (RAPT), a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.The UK drug company will pay $58 a share, equivalent to an equity value of $2.2 billion, according to a statement Tuesday. The price represents a premium of 65% compared with Rapt Therapeutics’ closing price of $35.10 on Monday.

See omnystudio.com/listener for privacy information.